List of Next-Gen Sequencing Companies in France - 11

Bio-Xtal is historically a provider of structural biology services. Since twelve years, our know-how in structural biology allowed us to perform projects ranging from domain definition to the structure resolution of protein/ligand or protein/protein interactions by Xray crystallography and NMR. We put an emphasis on monitoring the activity of our targets to ensure the relevance of the structural data we deliver. Our policy is to systematically develop home designed activity assays during our structural biology projects. Mastering eukaryotic and prokaryotic expression systems allows us to supply high quality protein for the needs of your compound screening as well as for structural studies of the selected compound’s complexes, guarantying the coherence of the results obtained on both sides A new key service from of Bio-Xtal is the cytosoluble single chain antibody fragment selection (Cytobody™). These can be raised against any antigen within a very short delay (4 weeks) and are very well expressed in either mammalian or bacteria cells. This allows their expression in Coli for large scale production and expression within mammalian cells for cellular biology applications. The applications of the Cytobodies ranges from the discovery of new druggable sites in multi-domain proteins to immuno-detection, cell imaging, protein purification, and protein stabilisation.

CliniSciences commercialises reagents (antibodies, recombinants, ELISA kits, RNAi, cDNA clones, probes, PCR/qPCR reagents...) to diagnostic and research labs. As very dynamic company, we do our best to be close to our customers'​ needs in terms of high quality reagents that we propose and in terms of service that we provide (search for a particular antibody, technical support, delivery time, etc.) Our principal assets for better serving you : adaptability, flexibility, reactivity and naturally the competence of the technical specialists at your service.

Depixus SAS, based in Paris, is a life science technology company pioneering a groundbreaking technology based on magnetic force spectroscopy. This innovative technology provides real-time analysis of individual biomolecular interactions at scale, enabling researchers to decode disease mechanisms and unlock faster routes to more effective therapies.

Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people's lives by learning from the wisdom of their adaptive immune systems. Adaptive's proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way diseases -- such as cancer, autoimmune conditions, and infectious diseases -- are diagnosed and treated. For more information, please visit adaptivebiotech.com.

IntegraGen is an OncoDNA group company specializing in the genomics of cancer and rare genetic diseases. Backed by highly competent and qualified teams, IntegraGen is a leading player in DNA sequencing services and genomic data interpretation software. The company runs one of the largest NGS labs in France and operates for research institutes of excellence. As part of OncoDNA group, IntegraGen leverages the power of next generation sequencing with the mission of delivering the promise of precision medicine to patients. IntegraGen has about 50 employees and generated €9 million of revenue in 2020. Based in France, IntegraGen is also present in the United States and is part of the OncoDNA group which works with an international network of 35 distributors. The Group also provides biomarker testing and clinical interpretation tools to guide treatment and monitoring of late stage solid tumors and accelerate the development of new cancer drugs. IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 - Mnemo: ALINT - Eligible PEA-PME).

MSInsight, a French health-tech company, empowers the fight against cancer by revealing actionable information from the genome. We are committed to developing a portfolio of state-of-the-art diagnostic solutions for Microsatellite Instability (MSI) status. MSI has been shown to be an indicator of treatment response, especially for immune checkpoint inhibitors, and as an important pan-cancer biomarker. We aim to propose bioinformatic tools for delivering insights on microsatellite mutational variations using Next-Generation Sequencing (NGS) data. Our flagship product, MSIcare, will be available as a robust diagnostic, prognostic, and theranostic assistant for guiding clinical decision-making.

At Novacyt, we pride ourselves on concentrating our expertise on specific market needs. Offering a comprehensive and developing portfolio of quality products, backed by proven supply and delivery services, to ensure the highest possible standards of customer service around the world. Our passion is for customer-centric solutions that advance the science behind diagnostics. This fuels our drive to deliver products that save lives and help in the fight against infectious disease. We offer an increasing portfolio of in-vitro diagnostic tests, utilising molecular and protein detection technologies – supporting healthcare and disease prevention across the globe in the clinical and life science sectors. Deep strengths in product development, commercialisation, contract design, and manufacturing ensure quality products and robust supply. Our Group has specialist experience and expertise throughout our business units: Primerdesign, Microgen Bioproducts, IT-IS international, and Lab21 Healthcare – creating solutions for the diagnostics industry, supplying an extensive range of high-quality assays and reagents worldwide.

PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection.The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurance managers/production managers.

Founded in 2017, SeqOne Genomics headquartered in Montpellier, France, is a fast-growing deep-tech company focused on turning genomic data into medically actionable insights in oncology, rare and inherited diseases. SeqOne clinical genomic analysis platform, powered by explainable AI, provides genomic labs and healthcare professionals with best-in-class accuracy, usability, and automation seamlessly across lab technologies. By streamlining complex multi-omics analysis workflows, we pave the way for a new era of personalized healthcare at scale, where genetic testing becomes as routine as traditional blood work, radically enhancing health outcomes for all. The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. It has been nominated twice for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club.

Xegen is a bioinformatics company specialized in Next Generation Sequencing (NGS) data analysis. We provide support for our customers or partners in their NGS data processing issues, through specific, automated, high added value bioinformatics analyzes. Xegen is developing Polypheme a bioinformatics suite dedicated to complex genes analysis (polymorphisms detection or allelic types). Polypheme analysis includes in particular HLA Typing, classic (HLA-A, -B, -C, DRB1, DQB1) and not classic genes (HLA-E, -F, -G, -H). Polypheme is also used to discover new alleles.

Ziwig ® is a French company whose ambition is to improve women’s health through a holistic approach and the development of products, services and a care ecosystem guided by science and the unique biology of each individual. This approach is supported by ongoing research excellence and is based on the close collaboration of medical experts and engineers specialized in cutting- edge technologies such as artificial intelligence and Next Generation human RNA Sequencing. Its functioning is based on an ecosystem, driven by the quest for excellence and patient centered, that uses disruptive technologies. This contributes to the emergence of precision medicine that is individualized, predictive and participatory, serving women’s well-being and quality of life. Ziwig’s work has resulted in several publications that have appeared in international peer-reviewed scientific journals such as diagnostics, Nature scientific reports and Journal of Clinical Medicine. Follow us on Instagram : https://www.instagram.com/ziwigfrance/